Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, is highlighted in a new NetworkNewsAudio APR titled “Chronic Rare Diseases in an Aging America:...
When a late-stage clinical trial reports response rates nearly double what researchers expected, yet the stock market barely reacts, seasoned analysts take notice and wonder if investors are missing something...
Soligenix (NASDAQ: SNGX), announces its inclusion in a BioMedWire editorial examining the urgent rise of chronic and rare diseases in aging populations. With more than 30 million Americans living with...
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire : — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the ...
Soligenix (NASDAQ: SNGX) was featured in a BioMedWire editorial titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,” which examines the growing burden of rare...
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- via BioMedWire : — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the ...
In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly...
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines. The company recently published a peer-reviewed summary of new scientific data demonstrating...
Soligenix (NASDAQ: SNGX) is entering a new phase of strategic breadth and influence with the appointment of a seasoned, high-level scientific and policy adviser who brings rarefied experience at the intersection...
In a key development that underscores the advancing clinical trajectory of its lead therapy, Soligenix (NASDAQ: SNGX) announced that the Data Monitoring Committee (“DMC”) overseeing its confirmatory...